公开(公告)号：WO2009097011A1

公开(公告)日：2009-08-06

申请号：PCT/US2008/073185

申请日：2008-08-14

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

Inventor： TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K31/4745 ,  A61K31/555 ,  A61K33/24

Abstract: Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents.

Abstract translation: 包含具有铂剂的受控释放的脂质体的组合物可用于实现增强的治疗效果，特别是当这些药物与其它治疗剂组合施用时。

公开(公告)号：WO2007076117A3

公开(公告)日：2007-11-01

申请号：PCT/US2006049245

申请日：2006-12-22

Applicant: CELATOR PHARMACEUTICALS INC ,  DICKO AWA ,  TARDI PAUL ,  MAYER LAWRENCE ,  JOHNSTONE SHARON

Inventor： DICKO AWA ,  TARDI PAUL ,  MAYER LAWRENCE ,  JOHNSTONE SHARON

IPC: A61K9/127

CPC classification number: A61K9/1278

Abstract: Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.

Abstract translation: 本文提供了包含具有可质子化氨基和仲或叔胺的治疗剂的脂质体组合物，以及用于包封这些治疗剂的方法。 一方面，本发明涉及包含三乙醇胺溶液中的伊立替康和任选地包含葡萄糖酸铜的脂质体制剂及其制备方法。

公开(公告)号：WO2007035783A2

公开(公告)日：2007-03-29

申请号：PCT/US2006/036569

申请日：2006-09-19

Applicant: CELATOR PHARMACEUTICALS, INC. ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

Inventor： JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127

Abstract: Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

Abstract translation: 包含稳定与胞苷类似物和铂剂相关的递送载体的组合物在施用这些药物的组合时可用于实现增强的治疗效果。

公开(公告)号：WO2003028697A2

公开(公告)日：2003-04-10

申请号：PCT/CA2002/001501

申请日：2002-10-03

Applicant: CELATOR TECHNOLOGIES INC. ,  TARDI, Paul ,  JOHNSTONE, Sharon ,  WEBB, Murray ,  BALLY, Marcel ,  ABRAHAM, Sheela

Inventor： TARDI, Paul ,  JOHNSTONE, Sharon ,  WEBB, Murray ,  BALLY, Marcel ,  ABRAHAM, Sheela

IPC: A61K9/00

CPC classification number: A61K31/7072 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K31/00 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention relates to encapsulation of drugs and other agents into liposomes.

Abstract translation: 本发明涉及药物和其它试剂在脂质体中的包封。

公开(公告)号：WO2007076117A2

公开(公告)日：2007-07-05

申请号：PCT/US2006/049245

申请日：2006-12-22

Applicant: CELATOR PHARMACEUTICALS, INC. ,  DICKO, Awa ,  TARDI, Paul ,  MAYER, Lawrence ,  JOHNSTONE, Sharon

Inventor： DICKO, Awa ,  TARDI, Paul ,  MAYER, Lawrence ,  JOHNSTONE, Sharon

IPC: C12Q1/68

CPC classification number: A61K9/1278

Abstract: Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.

Abstract translation: 本文提供了包含具有可质子化氨基和仲胺或叔胺的治疗剂的脂质体组合物，以及用于包封这些治疗剂的方法。 在一个方面，本发明涉及包含伊立替康在三乙醇胺溶液中并且任选地包含葡糖酸铜的脂质体制剂及其制备方法。

公开(公告)号：WO2006055903A1

公开(公告)日：2006-05-26

申请号：PCT/US2005/042131

申请日：2005-11-18

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  WEBB, Murray ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  MAYER, Lawrence

Inventor： TARDI, Paul ,  WEBB, Murray ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/1278

Abstract: This invention relates to encapsulation of drugs and other agents into preformed delivery vehicles.

Abstract translation: 本发明涉及将药物和其他药剂包封到预先形成的运载工具中。

公开(公告)号：WO2005102359A8

公开(公告)日：2005-12-15

申请号：PCT/CA2005000625

申请日：2005-04-22

Applicant: CELATOR PHARMACEUTICALS INC ,  MAYER LAWRENCE ,  JOHNSTONE SHARON ,  HARASYM TROY

Inventor： MAYER LAWRENCE ,  JOHNSTONE SHARON ,  HARASYM TROY

IPC: A61K9/127 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068

CPC classification number: A61K9/127 ,  A61K9/1278 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  Y10S977/801 ,  A61K2300/00

Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

Abstract translation: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素，多柔比星和伊达比星组，而优选的胞苷类似物选自阿糖胞苷，吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

公开(公告)号：WO2004087115A3

公开(公告)日：2004-10-14

申请号：PCT/CA2004/000507

申请日：2004-04-02

Applicant: CELATOR TECHNOLOGIES INC. ,  MAYER, Lawrence ,  BALLY, Marcel ,  WEBB, Murray ,  TARDI, Paul ,  JOHNSTONE, Sharon

Inventor： MAYER, Lawrence ,  BALLY, Marcel ,  WEBB, Murray ,  TARDI, Paul ,  JOHNSTONE, Sharon

IPC: A61K9/127

Abstract: Compositions which comprise liposomes having stably associated therewith a camptothecin and a fluoropyrimidine are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

公开(公告)号：WO2005102359A1

公开(公告)日：2005-11-03

申请号：PCT/CA2005/000625

申请日：2005-04-22

Applicant: CELATOR PHARMACEUTICALS, INC. ,  MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

Inventor： MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

IPC: A61K31/7068

CPC classification number: A61K9/127 ,  A61K9/1278 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  Y10S977/801 ,  A61K2300/00

Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in a liposomal carrier. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carrier are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

Abstract translation: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素，多柔比星和伊达比星组，而优选的胞苷类似物选自阿糖胞苷，吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

公开(公告)号：WO2004087115A2

公开(公告)日：2004-10-14

申请号：PCT/CA2004000507

申请日：2004-04-02

Applicant: CELATOR TECHNOLOGIES INC ,  MAYER LAWRENCE ,  BALLY MARCEL ,  WEBB MURRAY ,  TARDI PAUL ,  JOHNSTONE SHARON

Inventor： MAYER LAWRENCE ,  BALLY MARCEL ,  WEBB MURRAY ,  TARDI PAUL ,  JOHNSTONE SHARON

IPC: A61K9/127 ,  A61K31/00

CPC classification number: A61K31/4745 ,  A61K9/127 ,  A61K31/7072 ,  A61K2300/00

Abstract: Compositions which comprise liposomes having stably associated therewith a camptothecin and a fluoropyrimidine are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

Abstract translation: 包含稳定与喜树碱相关的脂质体和氟嘧啶的组合物在施用这些药物的组合时可用于获得增强的治疗效果。